视频

Botulinum neurotoxin formulations: overcoming the confusion

 

Authors Samizadeh S, De Boulle K

Received 13 November 2017

Accepted for publication 16 March 2018

Published 30 May 2018 Volume 2018:11 Pages 273—287

DOI https://doi.org/10.2147/CCID.S156851

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Andrew Yee

Peer reviewer comments 4

Editor who approved publication: Dr Jeffrey Weinberg

Abstract: Botulinum toxin A is produced by anaerobic spore-forming bacteria and is used for various therapeutic and cosmetic purposes. Botulinum toxin A injections are the most popular nonsurgical procedure worldwide. Despite an increased demand for botulinum toxin A injections, the clinical pharmacology and differences in formulation of commonly available products are poorly understood. The various products available in the market are unique and vary in terms of units, chemical properties, biological activities, and weight, and are therefore not interchangeable. For safe clinical practice and to achieve optimal results, the practitioners need to understand the clinical issues of potency, conversion ratio, and safety issues (toxin spread and immunogenicity). In this paper, the basic clinical pharmacology of botulinum toxin A and differences between onabotulinum toxin A, abobotulinum toxin A, and incobotulinum toxin A are discussed.
Keywords: botulinum toxin, botulinum neurotoxin, moiety, protein complexes


 

摘要视频链接Understanding Botulinum toxin A formulations